Fig. 4From: Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposureOverall survival landmark analysis of patients with treated secondary AML who underwent HSCT in first remission versus those who did not undergo transplant. Landmark analysis was performed from time of HSCT in the HSCT group and from the landmark time point (2.6Â months from start of AML therapy) in the non-HSCT groupBack to article page